The Relief Therapeutics Holding AG (OTCMKTS:RLFTF) stock has come back into focus among investors yet again and managed to clock gains of as much as 29% on Tuesday.
While the gains are expected to bring the stock into the attention of plenty of investors today, it is also necessary for investors to remember that there was no material news about Relief Therapeutics yesterday. However, at the same time, it might be useful to note that last week the company had announced that NRx Pharmaceuticals Inc, its collaboration partner and Quantum Leap Healthcare Collaborative made a key announcement.
It was announced by the two companies that they had started administering patients with inhaled aviptadil as part of the I-SPY COVID Trial. The trial in question is a form of phase 2 adaptive platform trial and is meant for bring about an improvement in the treatment of patients who might be critically ill from COVID 19 infection. It was a major announcement and one that might have far reaching implications for Relief Therapeutics as well. Considering the gains made by the stock yesterday, it is likely that the stock is going to be in focus among many investors this week.
Market Reaction:
On Monday, RLFTF stock surged 29% at $0.2470 with more than 11.19 million shares, compared to its average volume of 4.54 million shares. The stock had moved within a range of $0.1919 – 0.2540 after opening the trade at $0.1920. Over the past 52-week, the stock has been trading within a range of $0.1820 – 0.7600.
 stock Jumps to One Month High: Time to Buy?){kind=link}